Overview

Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis

Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)
Phase:
Phase 2
Details
Lead Sponsor:
Woolsey Pharmaceuticals
Treatments:
Fasudil